Uppsala, Sweden – April 21, 2026 – As previously communicated Orexo will announce the Interim Report for the first quarter of 2026 on April 28 at 7 am CEST.
At 2 pm the same day, analysts, investors and media are invited to a presentation where CEO Nikolaj Sørensen and CFO Fredrik Järrsten will present the latest developments. A Q&A session will follow the presentation.
The event will be streamed live, allowing participants to join via audiocast or teleconference by clicking the link below:
https://investorcaller.com/events/orexo/orexo-q1-report-2026
Registration is required to participate. Once you have registered, you will receive the information needed to join the conference call. Participants will be provided with a dial-in number, a conference ID and a personal user ID – all of which are required to access the call. Please note that questions can be asked via the conference call or submitted through the audiocast.
Prior to the event the presentation material will be available on the website under Investors/Report Archive
For further information contact:
Lena Wange
IR and Communications Director
+46 (0)18 780 88 00
ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company dedicated to advance treatments for severe diseases and life-saving rescue medications to meet future healthcare needs. At the core of our innovation is AmorphOX®, a proprietary drug delivery technology that improves bioavailability and stability for both large and small molecules, enabling new approaches to route of administration, manufacturing, and distribution. With over 30 years of experience and multiple drugs approved globally, Orexo is advancing a diversified pipeline of programs in clinical and preclinical development. The company collaborates with partners in research, development, and commercialization. Headquartered in Uppsala, Sweden, Orexo is listed on Nasdaq Stockholm’s main market and trades as ADRs on the OTCQX market in the United States.
For more information about Orexo visit, www.orexo.com. You can also follow Orexo on X, LinkedIn and YouTube.